Ovarian cancer develops in the ovaries, which are part of the female reproductive system. It is one of the most treatable cancers when detected early (Stage 1 & 2), with survival rates exceeding 90% when properly treated. However, due to vague symptoms, early detection remains a challenge.
Germany is a leading destination for ovarian cancer treatment, offering:
International patients benefit from Germany’s top gynecologic oncology specialists, cutting-edge hospitals, and innovative ovarian cancer treatment approaches.
Cancer is confined to one or both ovaries.
No spread to lymph nodes, abdominal tissues, or distant organs.
Cancer has spread beyond the ovaries to nearby pelvic organs (uterus, fallopian tubes, bladder, rectum, or peritoneum).
No distant metastases.
• Transvaginal ultrasound & CA-125 blood tests help detect ovarian cancer before it spreads.
• Genetic testing (BRCA1/BRCA2, MSI, TP53) guides personalized therapy selection.
• Procedure: Unilateral salpingo-oophorectomy (removal of one ovary & fallopian tube).
• Ideal for: Stage 1A or 1B patients who wish to have children.
• Cost: €15,000 – €35,000
• Prognosis: 95%+ survival rate when combined with careful monitoring.
• Procedure Performed laparoscopically, robotically, or via open surgery.
• Ideal for: Stage 1C & Stage 2 patients or those with genetic mutations (BRCA, TP53).
• Cost: €25,000 – €55,000
• Prognosis: 90%+ survival rate for early-stage disease.
• Procedure: Can be performed during primary surgery (hysterectomy).
• Ideal for: All early-stage ovarian cancer patients to ensure complete staging.
• Cost: €5,000 – €12,000
• Prognosis: Helps determine need for additional therapy.
• Procedure: Performed immediately after tumor removal.
• Ideal for: Stage 2 ovarian cancer with peritoneal involvement.
• Cost: €30,000 – €60,000
• Prognosis: Reduces recurrence risks by 30-50%.
• Common drugs: Carboplatin + Paclitaxel (standard regimen).
• Ideal for: High-risk Stage 1C & all Stage 2 cases.
• Cost: €10,000 – €30,000 per cycle
• Prognosis: Enhances survival & prevents recurrence.
• Ideal for : Patients with residual disease after surgery.
• Cost: €50,000 – €100,000 per treatment plan
• Prognosis: Improves local control while reducing side effects.
• Types:
PARP inhibitors (Olaparib, Niraparib): For BRCA-mutated ovarian cancer.
Anti-VEGF Therapy (Bevacizumab): Prevents blood vessel growth in tumors.
Checkpoint Inhibitors (Pembrolizumab): For MSI-high or PD-L1-positive tumors.
• Cost: €40,000 – €90,000 per treatment plan
• Prognosis: Extends survival & prevents recurrence.
Definition: Dendritic cells (DCs) are modified to recognize and destroy ovarian cancer cells, strengthening the immune system.
• Best for:
• Cost: €30,000 – €60,000 per treatment plan plan
• Prognosis: Boosts immune response & reduces recurrence risk.
Top Pancreatic Cancer Specialists in Germany
Germany is a global leader in ovarian cancer treatment, offering fertility-preserving surgery, HIPEC, proton therapy, and dendritic cell immunotherapy.
Submit your request now! You will receive an individual evaluation of your case within 48 hours and get a scheduled appointment within 3 weeks to start your recovery journey with WEGOVITA.